How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: The original drug or switching to a second EGFR-TKI?

Chinese Journal of Lung Cancer

Volumn 16, Issue 7, 2013, Pages 345-352

  Tang, Chuanhao ^a   Li, Xiaoyan ^a   Guo, Wanfeng ^a   Li, Jianjie ^a   Qin, Haifeng ^a   Wang, Weixia ^a   Qu, Lili ^a   An, Juan ^a   Gao, Hongjun ^a   Liu, Xiaoqing ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Epidermal growth factor receptor; Erlotinib; Gefitinib; Lung neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ARTICLE; COMPARATIVE STUDY; DISEASE CONTROL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGRESSION FREE SURVIVAL;

EID: 84922687303     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2013.07.03     Document Type: Article

References (17)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
2. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
4. Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
5. Zhang L, Ma SL, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol, 2012, 13(5): 466-475.
6. Wu YL, Kim JH, Park K, et al. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer, 2012, 77(2): 339-345.
7. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatinpaclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013, 24(1): 54-59.
8. Watanabe S, Tanaka J, Ota T, et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11: 1.
9. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer, 2010, 68(1): 99-104.
10. Hata A, Katakami N, Yoshioka H, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer, 2011, 74(2): 268-273.
11. Becker A, Crombag L, Heideman DA, et al. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer, 2011, 47(17): 2603-2606.
12. Oh IJ, Ban HJ, Kim KS, et al. Retreatment of gefitinib in patients with nonsmall- cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study. Lung Cancer, 2012, 77(1): 121-127.
13. Namba Y, Imamura F, Morita S, et al. Dose gefitinib re-challenge or treatment beyond progression (TBP) prolong survival of NSCLC patients?-Real World Evidence from Gefitinib Treatment Responders. 2012 ESMO Abstract: 1253P.
14. Kosaka T, Yamaki E, Mogi A, et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol, 2011, 2011: 15214.
15. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 2008, 14(10): 2895-2899.
16. Sequist LV, Waltman BA, Dias-Santagata, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3(75): 75ra26.
17. Lin L, Bivona TG. Mechanisms of epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract, 2012, 2012: 817297.